Kenvue (HAM:J4D) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:J4D Kenvue Inc HAM:J4D
70 GF Score
Price €17.04
GF Value €17.84
! 6 Warning Signs
View Full Analysis

What is Kenvue FFO?

FFO (Funds from operations) only applies to REITs.

HAM:J4D
70GF Score
Kenvue Inc HAM:J4D
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kenvue (HAM:J4D) Overvalued in 2026?

Based on GuruFocus' analysis, Kenvue stock appears to be undervalued. The current stock price of €17.04 is trading 4.5% below its estimated GF Value™ of €17.84.

Key valuation signals for HAM:J4D:

  • FFO:
  • GF Value™: €17.84 vs. price of €17.04 (4.5% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the HAM:J4D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kenvue Business Description

Address 1 Kenvue Way, Summit, NJ, USA, 07901
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
70GF Score

Get the complete analysis for HAM:J4D

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.04
Price
€17.84
GF Value